Literature DB >> 33915773

BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19.

Rui-Ru Ji1, Yajin Qu2, Hua Zhu2, Yumei Yang1, Annette B Vogel3, Ugur Sahin3,4, Chuan Qin2, Aimin Hui1.   

Abstract

BNT162b2 is a highly efficacious mRNA vaccine approved to prevent COVID-19. This brief report describes the immunogenicity and anti-viral protective effect of BNT162b2 in hACE2 transgenic mice. Prime-boost immunization with BNT162b2 elicited high titers in neutralizing antibodies against SARS-CoV-2, which correlated with viral clearance and alleviated lung lesions in these mice after viral challenge.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; challenge study; efficacy; immunogenicity; mRNA vaccine

Year:  2021        PMID： 33915773     DOI： 10.3390/vaccines9040324

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN： 2076-393X


  6 in total

Review 1.  Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies.

Authors:  Lanying Du; Yang Yang; Xiujuan Zhang; Fang Li
Journal:  Nanoscale       Date:  2022-01-27       Impact factor: 7.790

Review 2.  The Development of mRNA Vaccines for Infectious Diseases: Recent Updates.

Authors:  Jiao Wei; Ai-Min Hui
Journal:  Infect Drug Resist       Date:  2021-12-09       Impact factor: 4.003

3.  mRNA Vaccines Induce Rapid Antibody Responses in Mice.

Authors:  Makda S Gebre; Susanne Rauch; Nicole Roth; Janina Gergen; Jingyou Yu; Xiaowen Liu; Andrew C Cole; Stefan O Mueller; Benjamin Petsch; Dan H Barouch
Journal:  bioRxiv       Date:  2021-11-02

Review 4.  Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics.

Authors:  Sean C Semple; Robert Leone; Christopher J Barbosa; Ying K Tam; Paulo J C Lin
Journal:  Pharmaceutics       Date:  2022-02-11       Impact factor: 6.321

5.  A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.

Authors:  Patricia Pérez; Adrián Lázaro-Frías; Carmen Zamora; Pedro J Sánchez-Cordón; David Astorgano; Joanna Luczkowiak; Rafael Delgado; José M Casasnovas; Mariano Esteban; Juan García-Arriaza
Journal:  Front Immunol       Date:  2022-01-27       Impact factor: 7.561

6.  A single immunization with cellular vaccine confers dual protection against SARS-CoV-2 and cancer.

Authors:  Kanako Shimizu; Shogo Ueda; Masami Kawamura; Mikiko Satoh; Shin-Ichiro Fujii
Journal:  Cancer Sci       Date:  2022-06-07       Impact factor: 6.518
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.